23 February 2016
EUCAST Guidance Documents in susceptibility testing
- Direct susceptibility testing (16 Feb 2012)
- Oral cephalosporins and Enterobacterales breakpoints (14 July, 2020). Previous version (16 Feb 2012)
- Stenotrophomonas maltophilia (1 Feb 2012)
- Burkholderia cepacia complex (20 July, 2013)
- Breakpoints for topical use of antimicrobial agents (revised 21 November, 2019; previoud version valid until 131 December, 2019): Breakpoints for topical use of antimicrobial agents (22 Dec, 2016 - 31 December 2019)
- Daptomycin in endocarditis and bloodstream infections caused by enterococci (also available in CMI as a EUCAST position paper; 2020)
- Recommendations for colistin (polymyxin E) MIC testing - joint EUCAST and CLSI recommendation (22 March, 2016)
- What to do when there are no breakpoints in the EUCAST breakpoint table (5 July, 2016)
- Legionella pneumophila susceptibility testing (9 September, 2016; updated 11 December, 2017)
- Setting breakpoints for agent-inhibitor combinations (2 October, 2017)
- EUCAST system for antimicrobial abbreviation (13 July, 2018)
- Guidance on the 2019 modifications of susceptibility categories S, I and R categories (22 October, 2018). This presentation also informs laboratories on how to implement the Area of Technical Uncertainty.
- ATU - the Area of Technical Uncertainty - Guidance to laboratories on how to deal with the ATU in antimicrobial susceptibility testing (21 Dec, 2018; update 2 Jan, 2019, update 1 June, 2020).
Graphs to illustrate ATUs. - Guidance document on tigecycline dosing - in relation to EUCAST breakpoints for tigecycline 2019 (23 December, 2018)
- Guidance on cefotaxime and ceftazidime disks with and without clavulanic acid for ESBL confirmation (12 February, 2019)
- Guidance for industry on the working order between pharmaceutical industry,
EMA and EUCAST (5 May, 2019) - Guidance on the implementation and use of the 2020 revised aminoglycoside breakpoints (first published 21 Jan, 2020; updated April 2020)
